GL1X · GenesisL1 explorer

Research workbench

Selection of a novel highly specific tnfalpha antagonist: insight from the crystal structure of the antagonist-tnfalpha complex

Analyse Selection of a novel highly specific tnfalpha antagonist: insight from the… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3L9J
Type
protein
Length
279 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Tnfalpha; Tumor necrosis factor, soluble form
UniProt
P01375
Ligands
MG
Pockets
1 · best druggability 0.48

Structure

x-ray diffraction · 2 distinct chains · 11% helix, 42% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
CTnfalphaprotein13022% helix, 32% strand—
TTumor necrosis factor, soluble formprotein1492% helix, 51% strandP01375

Ligands and binding sites

  • MG · Magnesium ion · metal · chains C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12000.480.7527empty

Interfaces

1 interface between chains.

  • C–T · 901 Ų buried · 13 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 disulfide (disulfide).

Compared structures

  • 3L9J · Selection of a novel highly specific TNFalpha antagonist: Insight from the crystal… · the same entry in another collection · chain C against C, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.